Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.77% | 31.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.13% | 17.46% | |||
| Operating Income | -29.13% | -17.46% | |||
| Income Before Tax | -18.82% | -18.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.88% | -18.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.88% | -18.29% | |||
| EBIT | -29.13% | -17.46% | |||
| EBITDA | -29.15% | -17.46% | |||
| EPS Basic | 75.99% | 91.60% | |||
| Normalized Basic EPS | 76.20% | 91.60% | |||
| EPS Diluted | 75.99% | 91.60% | |||
| Normalized Diluted EPS | 76.20% | 91.60% | |||
| Average Basic Shares Outstanding | 399.26% | 1,308.41% | |||
| Average Diluted Shares Outstanding | 399.26% | 1,308.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||